Department of Medicine.
Division of Gastroenterology and Hepatology.
J Clin Gastroenterol. 2022 Oct 1;56(9):e318-e322. doi: 10.1097/MCG.0000000000001731. Epub 2022 Jul 22.
The goal of this study was to compare the relative safety of administering iron infusions on the same day as intravenous (IV) biological therapy to the administration of these treatments on different days in patients with inflammatory bowel disease (IBD).
IV iron therapy is often required in patients with IBD. Many patients with IBD who receive IV iron therapy in the outpatient setting also receive biological infusion therapy for treatment of their IBD.
Patients with IBD who received IV iron therapy at a single infusion center were included. We compared documented infusion-related reactions in patients with patients receiving an iron infusion on the same day as their biological infusion to those who received their iron infusion on a different day.
Among 481 patients, 129 received an iron infusion on the same day as a biologic infusion. There was no significant difference in the incidence of infusion reaction when comparing patients who received biological infusion therapy in the same session as the iron infusion to those patients who received a biological infusion on a different day (5% vs. 7%, P =0.246) or any IBD-related therapy (5% vs. 8%, P =0.206).
The frequency and type of infusion reactions in patients receiving IV iron therapy on the same day after IV therapy with biologics was not increased compared with patients who received a biological infusion on a different day. A sequential infusion of biological therapy followed by IV iron therapy may be a safe and cost-effective approach.
本研究旨在比较在炎症性肠病(IBD)患者中,同日给予静脉(IV)生物治疗与不同日给予这些治疗的相对安全性。
IBD 患者常需要 IV 铁治疗。许多在门诊接受 IV 铁治疗的 IBD 患者也接受 IV 铁治疗用于治疗其 IBD。
纳入在单一输注中心接受 IV 铁治疗的 IBD 患者。我们比较了同一天接受铁输注和不同日接受铁输注的患者记录的输注相关反应。
在 481 例患者中,129 例在同一天接受了铁输注和生物输注。与同一天接受生物输注治疗的患者相比,同一天接受铁输注和生物输注的患者(5% vs. 7%,P=0.246)或任何 IBD 相关治疗(5% vs. 8%,P=0.206)的输注反应发生率无显著差异。
与同一天接受生物输注的患者相比,同日接受 IV 铁治疗的患者的 IV 铁治疗后输注反应的频率和类型并未增加。生物治疗后序贯输注 IV 铁治疗可能是一种安全且具有成本效益的方法。